
    
      This study is a multi-center, prospective, real-world study, aiming to investigate the use of
      Glecaprevir/Pibrentasvir in routine clinical management of chronic hepatitis C patients and
      evaluate its effectiveness and safety across a heterogeneous population in
      China.Approximately 800 patients will take part in this study, 20 sites will be included
      which distribute in China's major cities, thus each site will enroll 40 patients.
    
  